EMEA-001314-PIP01-12-M01
Key facts
| Invented name |
Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)
|
| Active substance |
Dinutuximab beta
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0093/2022
|
| PIP number |
EMEA-001314-PIP01-12-M01
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of neuroblastoma
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
EUSA Pharma (Netherlands) B.V.
Tel. +44 (0)3305 001155 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|